NCT03197779View on ClinicalTrials.gov

A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

691

Participants

Timeline

Start Date

November 18, 2013

Primary Completion Date

February 2, 2016

Study Completion Date

January 24, 2017

Conditions
Thrombosis
Interventions
DRUG

BMS-962212

Intravenous Infusion administration over 2 hours or 5 days

DRUG

Aspirin

Oral administration

OTHER

Placebo

Oral administration

Trial Locations (3)

21225

Parexel International - Baltimore Epcu, Baltimore

90630

Wcct Global, Llc, Cypress

91206

California Clinical Trials Medical Group, Glendale

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03197779 - A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects | Biotech Hunter | Biotech Hunter